Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2017

View Archived Issues

Mast Therapeutics and Savara enter merger agreement

Ramot describes drug conjugates for cancer

Jiangsu Hengrui Medicine patent reports SERDs

Houston Methodist studies tilarginine acetate for triple-negative breast cancer

KemPharm's KP-511 shows promising results in phase I study

Esperion begins pivotal efficacy studies and cardiovascular outcomes study of bempedoic acid

GSK nominates second target under Adaptimmune collaboration

AdAlta reports additional preclinical data for AD-114 in lung and liver fibrosis

Allergan purchases exclusive option right to acquire Lysosomal Therapeutics

Lexicon Pharmaceuticals begins dosing in phase I trial of LX-2761

NeuroGenetic completes phase I studies for Alzheimer's candidate

Taiwan Liposome reports topline results from phase I/II study of TLC-599

First patient treated in phase I study of RG-6016 for SCLC

Bayer patents GLUT-1 inhibitors

Novartis describes SHP-2 inhibitors

Sanofi and ImmuNext to jointly develop INX-021

Actelion Pharmaceuticals reveals NOX4 inhibitors for fibrosis

Apodemus prepares and tests PI4Kbeta inhibitors

Valeant reports positive results from second phase III study of psoriasis drug

Positive phase II results presented for Debio-1450 in patients with ABSSSI

Astellas terminates agreement with UMN Pharma for influenza vaccine programs

Targeting Pol I as a novel therapeutic strategy for preventing arterial restenosis

MRTF inhibition results in marked reduction in lung metastases in RhoC-overexpressing melanoma

Bortezomib as potential new therapeutic option for patient with severe anti-NMDAR encephalitis

SBI Biotech enters agreement with Kyowa Hakko Kirin for SBI-9674

Sarepta signs agreements with Nationwide Children's Hospital for gene therapy programs

FDA approves Egalet's Arymo ER tablets

Mikeluna launched in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...